Skip to Content

Cobicistat Dosage

Medically reviewed on September 25, 2017.

Applies to the following strengths: 150 mg

Usual Adult Dose for:

Additional dosage information:

Usual Adult Dose for HIV Infection

150 mg orally once a day with food

-This drug must be used with atazanavir or darunavir; the manufacturer product information for these agents should be consulted.
-This drug may be used with atazanavir (300 mg orally once a day) in therapy-naive and therapy-experienced patients.
-This drug may be used with darunavir (800 mg orally once a day) in therapy-naive patients and therapy-experienced patients with no darunavir resistance associated substitutions.
-This drug is not interchangeable with ritonavir and should not be used with darunavir 600 mg twice a day, fosamprenavir, saquinavir, or tipranavir.

Use: To increase systemic exposure of atazanavir or darunavir in combination with other antiretrovirals in the treatment of HIV-1 infection

Renal Dose Adjustments

No adjustment recommended.

CrCl less than 70 mL/min: Coadministration with tenofovir is not recommended.

Liver Dose Adjustments

Mild or moderate liver dysfunction (Child-Pugh A or B): No adjustment recommended.
Severe liver dysfunction (Child-Pugh C): Data not available


Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.


Data not available

Comments: This drug is highly protein-bound; significant removal via hemodialysis or peritoneal dialysis is not likely.

Other Comments

Administration advice:
-Use in combination with atazanavir or darunavir and other antiretroviral drugs.
-Administer with food at the same time as atazanavir or darunavir.
-Consult the manufacturer product information regarding missed doses.

Storage requirements:
-Store at 25C (77F); excursions permitted to 15C to 30C (59F to 86F).
-Store and dispense in original container; keep bottle tightly closed.

-The manufacturer product information for atazanavir or darunavir and other coadministered antiretroviral drugs should be consulted for further guidance.

-Metabolic: Serum phosphorus in patients at risk of renal dysfunction (when used with tenofovir)
-Renal: Estimated CrCl (before starting therapy); for renal safety (if serum creatinine increases more than 0.4 mg/dL from baseline); estimated CrCl, urine glucose, and urine protein (at baseline and routinely during therapy [when used with tenofovir])

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.